Literature DB >> 16159021

Creating the next generation of protein therapeutics through rational drug design.

David E Szymkowski1.   

Abstract

Biopharmaceuticals, or protein drugs, have proven to be safe and effective therapies in many disease indications. However, the first generation of biopharmaceuticals has largely been limited to replicating the functions of native human proteins, or inhibiting these functions through the use of monoclonal antibodies. Recent advances in the design of biopharmaceuticals include computational approaches to manipulate protein structure, improved screening processes to synthesize and assay libraries of novel proteins, and new methods to modify proteins post-translationally and during production. Protein drug structure and function can now be optimized in the same way that small molecules are optimized via medicinal chemistry. This review addresses recent developments in the field of protein 'medicinal biology', and provides examples of how these tools are being applied to create the next generation of biopharmaceuticals possessing optimized drug properties and novel functions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159021

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  13 in total

Review 1.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

2.  Development of transfection and high-producer screening protocols for the CHOK1SV cell system.

Authors:  M Celina de la Cruz Edmonds; Melanie Tellers; Christine Chan; Peter Salmon; David K Robinson; Julia Markusen
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

3.  A program for ligation at threonine sites: application to the controlled total synthesis of glycopeptides.

Authors:  Jin Chen; Ping Wang; Jianglong Zhu; Qian Wan; Samuel J Danishefsky
Journal:  Tetrahedron       Date:  2010-03-27       Impact factor: 2.457

4.  Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry.

Authors:  William Burkitt; Paula Domann; Gavin O'Connor
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

5.  Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein.

Authors:  Zhigang Zhou; Mansoora Khaliq; Jae-Eun Suk; Chinmay Patkar; Long Li; Richard J Kuhn; Carol Beth Post
Journal:  ACS Chem Biol       Date:  2008-12-19       Impact factor: 5.100

6.  Toward fully synthetic homogeneous beta-human follicle-stimulating hormone (beta-hFSH) with a biantennary N-linked dodecasaccharide. synthesis of beta-hFSH with chitobiose units at the natural linkage sites.

Authors:  Pavel Nagorny; Bernhard Fasching; Xuechen Li; Gong Chen; Baptiste Aussedat; Samuel J Danishefsky
Journal:  J Am Chem Soc       Date:  2009-04-29       Impact factor: 15.419

7.  Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches.

Authors:  Cedric E Bobst; Rinat R Abzalimov; Damian Houde; Marek Kloczewiak; Rohin Mhatre; Steven A Berkowitz; Igor A Kaltashov
Journal:  Anal Chem       Date:  2008-08-27       Impact factor: 6.986

Review 8.  Site-Specific PEGylation of Therapeutic Proteins.

Authors:  Jonathan K Dozier; Mark D Distefano
Journal:  Int J Mol Sci       Date:  2015-10-28       Impact factor: 5.923

9.  PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1).

Authors:  Jyotica Batra; Jessica Robinson; Christine Mehner; Alexandra Hockla; Erin Miller; Derek C Radisky; Evette S Radisky
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

Review 10.  TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.

Authors:  Melissa K McCoy; Malú G Tansey
Journal:  J Neuroinflammation       Date:  2008-10-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.